Optical imaging with Her2-targeted affibody molecules can monitor Hsp90 treatment response in a breast cancer xenograft mouse model

Clinical Cancer Research

Volumn 18, Issue 4, 2012, Pages 1073-1081

  Van De Ven, Stephanie M W Y ^a,b,d   Elias, Sjoerd G ^a,b,d   Chan, Carmel T ^a,b   Miao, Zheng ^a,b   Cheng, Zhen ^a,b   De, Abhijit ^a,b,e   Gambhir, Sanjiv S ^a,b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c Stanford University   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALVESPIMYCIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMAGE DISPLAY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; BENZOQUINONES; BREAST NEOPLASMS; DOWN-REGULATION; FEMALE; GENE EXPRESSION; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MICE; MICE, NUDE; MOLECULAR IMAGING; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84857095821     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3213     Document Type: Article

References (29)

1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45: 228-47.
2. Woodhams R, Kakita S, Hata H, Iwabuchi K, Kuranami M, Gautam S, et al. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging-comparison with contrast- enhanced MR imaging and pathologic findings. Radiology 254:357-66.
3. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S-50S.
4. van de Ven S, Wiethoff A, Nielsen T, Brendel B, van der Voort M, Nachabe R, et al. A novel fluorescent imaging agent for diffuse optical tomography of the breast: first clinical experience in patients. Mol Imaging Biol 2010;12:343-8.
5. van de Ven SM, Elias SG, Wiethoff AJ, van der Voort M, Nielsen T, Brendel B, et al. Diffuse optical tomography of the breast: preliminary findings of a new prototype and comparison with magnetic resonance imaging. Eur Radiol 2009;19:1108-13.
6. Zhu Q, Cronin EB, Currier AA, Vine HS, Huang M, Chen N, et al. Benign versus malignant breast masses: optical differentiation with US-guided optical imaging reconstruction. Radiology 2005;237:57-66. (Pubitemid 41346146)
7. Cerussi A, Hsiang D, Shah N, Mehta R, Durkin A, Butler J, et al. Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy. Proc Natl Acad Sci U S A 2007;104: 4014-9. (Pubitemid 47181570)
8. Rinneberg H, Grosenick D, Moesta KT, Mucke J, Gebauer B, Stroszczynski C, et al. Scanning time-domain optical mammography: detection and characterization of breast tumors in vivo. Technol Cancer Res Treat 2005;4:483-96. (Pubitemid 41446802)
9. Floery D, Helbich TH, Riedl CC, Jaromi S, Weber M, Leodolter S, et al. Characterization of benign and malignant breast lesions with computed tomography laser mammography (CTLM): initial experience. Invest Radiol 2005;40:328-35. (Pubitemid 40734560)
10. Jiang S, Pogue BW, Carpenter CM, Poplack SP, Wells WA, Kogel CA, et al. Evaluation of breast tumor response to neoadjuvant chemotherapy with tomographic diffuse optical spectroscopy: case studies of tumor region-of-interest changes. Radiology 2009;252:551-60.
11. Intes X. Time-domain optical mammography SoftScan: initial results. Acad Radiol 2005;12:934-47. (Pubitemid 41116410)
12. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nat Med 2003;9:123.
13. Pierce MC, Javier DJ, Richards-Kortum R. Optical contrast agents and imaging systems for detection and diagnosis of cancer. Int J Cancer 2008;123:1979-90.
14. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26. (Pubitemid 34111379)
15. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007;26:6469-87. (Pubitemid 47530601)
16. Capala J, Bouchelouche K. Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy. Curr Opin Oncol 2010;22:559-66.
17. Orlova A, Wallberg H, Stone-Elander S, Tolmachev V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009;50:417-25.
18. Cheng Z, De Jesus OP, Namavari M, De A, Levi J, Webster JM, et al. Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med 2008;49:804-13. (Pubitemid 351717547)
19. Ren G, Zhang R, Liu Z, Webster JM, Miao Z, Gambhir SS, et al. A2-helix small protein labeled with 68Ga for PET imaging of HER2 expression. J Nucl Med 2009;50:1492-9.
20. Baum RP, Prasad V, Muller D, Schuchardt C, Orlova A, Wennborg A, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med 2010;51:892-7.
21. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72. (Pubitemid 41400776)
22. Zsebik B, Citri A, Isola J, Yarden Y, Szollosi J, Vereb G. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett 2006;104: 146-55. (Pubitemid 43330721)
23. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002;8:986-93. (Pubitemid 34517631)
24. Keren S, Gheysens O, Levin CS, Gambhir SS. A comparison between a time domain and continuous wave small animal optical imaging system. IEEE Trans Med Imaging 2008;27:58-63.
25. Schwock J, Dhani N, Cao MP, Zheng J, Clarkson R, Radulovich N, et al. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts. Cancer Res 2009;69:4750-9.
26. Lee SB, Hassan M, Fisher R, Chertov O, Chernomordik V, Kramer- Marek G, et al. Affibody molecules for in vivo characterization of HER2- positive tumors by near-infrared imaging. Clin Cancer Res 2008;14: 3840-9.
27. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18FFDG PET. J Nucl Med 2006;47:793-6. (Pubitemid 46768442)
28. Oude Munnink TH, Korte MA, Nagengast WB, Timmer-Bosscha H, Schroder CP, Jong JR, et al. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur J Cancer 2010;46:678-84.
29. Kramer-Marek G, Kiesewetter DO, Martiniova L, Jagoda E, Lee SB, Capala J. [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 2008;35:1008-18.